Blocking blood supply to treat glioblastoma
Official title: Research on the Safety and Efficacy of Blocking Dural Blood Supply in Glioblastoma Patients
Run by First Affiliated Hospital, Sun Yat-Sen University · NCT05990556 · Data updated 2026-11-12
This study is testing a new procedure that blocks blood flow to glioblastoma tumors to see if it can help the immune system fight the cancer better in people who haven't had treatment yet.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 70 Years |
| Sex | All |
| Enrollment | 20 (estimated) |
| Sponsor | First Affiliated Hospital, Sun Yat-Sen University Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Guangzhou, Guangdong) |
| Status | Recruiting |
| Started | May 11, 2024 |
| Main results expected | September 1, 2025 |
| Study ends | September 1, 2028 |
| Registry record updated | July 24, 2024 |
| Trial ID | NCT05990556 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are patients with a confirmed diagnosis of glioblastoma who have not received prior treatments.
✕Probably not a fit
Patients whose glioblastoma diagnosis is later confirmed to be incorrect or those with significant comorbidities affecting survival may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study investigates the safety and efficacy of an interventional procedure aimed at blocking the blood supply from the meningeal arteries in patients diagnosed with glioblastoma. The approach is based on the hypothesis that altering the immune microenvironment can enhance the effectiveness of immune responses against the tumor. Eligible participants include those who have not undergone prior treatments for their glioblastoma, allowing for a clearer assessment of the intervention's impact. The study aims to provide insights into how manipulating blood supply can influence tumor progression and immune activation.
Why it matters
Potential benefit: If successful, this approach could lead to improved treatment outcomes for glioblastoma patients by enhancing immune responses against the tumor.
How similar studies have gone: While there is ongoing research into the immune microenvironment of glioblastoma, this specific approach of blocking meningeal blood supply is novel and has not been extensively tested in prior studies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Imaging or needle biopsy pathologically diagnosed as glioblastoma * Patients have not previously received radiotherapy, chemotherapy and other treatment modalities for intracranial lesions * There are no related contraindications such as neurovascular intervention and craniotomy Exclusion Criteria: * The patient's initial imaging diagnosis was glioblastoma, and the postoperative pathology confirmed nonglioblastoma * The patient has other underlying medical conditions that affect survival time * The patient had other underlying medical conditions that affected follow-up or quality of life assessment * Patients do not have the above exclusion criteria and refuse to participate in clinical trials after informed consent
Where it's running
-
the First Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China Recruiting
Study contacts
- Principal investigator: Nu Zhang, Professor — First Affiliated Hospital, Sun Yat-Sen University
- Study coordinator: Nu Zhang, Professor
- Email: zhangnu2@mail.sysu.edu.cn
- Phone: 13825070717
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
YN003 injection in glioma patients
This phase 1 study tests whether YN003 injected IV is safe and tolerable for adults with recurrent or progressive glioma, and to explore how the drug behaves in the body and any early signs of activity.
-
Brain connectome project in adults with brain glioma undergoing surgery
This registry collects MRI data and clinical information from adults with glioma to see how brain networks relate to surgery and recovery.
-
Lixumistat window of opportunity in newly diagnosed glioblastoma
This study tests whether Lixumistat can benefit adults with newly diagnosed glioblastoma who are planned for surgical tumor removal.
-
Glioblastoma in Réunion: an epidemiological and socio-anthropological look at patients and care
A large group of adults with diffuse gliomas in Réunion is being studied to understand how biology, culture, and health care pathways affect diagnosis and treatment.
-
Butterfly glioblastoma: test adding 5-ALA PoMA with LIDU ultrasound to standard care
This early-phase study tests whether adding 5-ALA–mediated activation with LIDU ultrasound is safe and tolerable for adults with newly diagnosed butterfly glioblastoma, before or during standard chemotherapy and radiotherapy.
-
Maintenance radiotherapy after standard glioblastoma treatment
This study tests whether a single 2 Gy maintenance radiotherapy dose after standard treatment is safe and feasible for adults with newly diagnosed glioblastoma.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.